NEW YORK (GenomeWeb News) – Proteome Sciences will supply its tandem mass tag — or TMT — technology to German drug discovery company Cellzome, Proteome Sciences announced today.
 
Cellzome was an early beta test site for Proteome Sciences’ TMTsixplex, which allows up to six samples to be labeled, mixed, and subsequently identified. Now, Cellzome plans to apply the TMTsixplex technology to its own proteomics platform approach for analyzing protein-drug and protein-protein interactions.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.